Related Experiment Video
Updated: May 5, 2026

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
Published on: December 28, 2010
Prospects of therapy for infections with human T-lymphotropic virus type III
Abstract:
Human T-lymphotropic virus type III is susceptible to attack at various sites during its replicative cycle. Inhibitors of reverse transcriptase activity, including suramin, antimoniotungstate (HPA-23), and trisodium phosphonoformate, have shown in-vitro activity against the virus in early clinical trials. Other significant antiviral agents are recombinant interferon alpha-A, ribavirin, and ansamycin. Double-blind, placebo-controlled clinical trials of interferon alpha, which inhibits viral replication at easily achievable serum levels, are underway. The development of optimal therapeutic regimens will require carefully controlled, multicenter collaborative trials with standardized criteria for evaluating responses. Prolonged treatment with combinations of antiviral and immunomodulating agents may be necessary for control of HTLV-III replication and for effective treatment of the acquired immunodeficiency syndrome.
Insights
Researchers are exploring antiviral drugs like suramin and interferon alpha to combat Human T-lymphotropic virus type III (HTLV-III) replication. Combination therapies may be key for treating acquired immunodeficiency syndrome.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Human T-lymphotropic virus type III (HTLV-III) is a significant pathogen.
- The virus has multiple targets within its replicative cycle.
Purpose of the Study:
- To review current antiviral agents and therapeutic strategies for HTLV-III.
- To highlight the need for controlled clinical trials in managing HTLV-III infection and acquired immunodeficiency syndrome (AIDS).
Main Methods:
- Review of in-vitro studies and early clinical trials of antiviral agents.
- Discussion of ongoing double-blind, placebo-controlled trials for interferon alpha.
- Emphasis on the necessity of multicenter collaborative trials.
Main Results:
- Several inhibitors of reverse transcriptase, including suramin, HPA-23, and trisodium phosphonoformate, show in-vitro activity.
- Recombinant interferon alpha-A, ribavirin, and ansamycin are identified as significant antiviral agents.
- Interferon alpha demonstrates efficacy in inhibiting viral replication at achievable serum levels.
Conclusions:
- Optimal therapeutic regimens for HTLV-III require carefully controlled, multicenter trials.
- Prolonged combination therapy with antiviral and immunomodulating agents may be necessary for effective HTLV-III replication control and AIDS treatment.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Endocarditis III: Medical Management
Myocarditis III: Medical Management

